Matlock Jeffries, MD, FACP, FACR
Oklahoma Medical Research Foundation
Oklahoma City, OK, United States
Disclosure information not submitted.
Nancy Lane, MD, BA
University of California at Davis, School of Medicine
Hillsborough, California, United States
Disclosure(s): Merck: Advisor or Review Panel Member (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Novo Nordisk: Consultant (Ongoing)
Matlock Jeffries, MD, FACP, FACR
Oklahoma Medical Research Foundation
Oklahoma City, OK, United States
Disclosure information not submitted.
Nancy Lane, MD, BA
University of California at Davis, School of Medicine
Hillsborough, California, United States
Disclosure(s): Merck: Advisor or Review Panel Member (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Novo Nordisk: Consultant (Ongoing)
This session will review the latest data from both basic science and clinical perspectives regarding the potential use of GLP1 agonist medications in the treatment of osteoarthritis.
Speaker: C. Thomas Appleton, MD, PhD, FRCPC – Western University
Speaker: Francis Berenbaum, MD, PhD – Sorbonne University - Saint-Antoine hospital